Autenrieth, M;Gschwend, JE;Nawroth, R;Retz, M
The significance of extended pelvic lymphadenectomy for muscle invasive bladder cancer
Onkologe
2012
18
11
985-+

Kubler, H;Gschwend, JE
Muscle-invasive bladder cancer
Onkologe
2012
18
11
977-+

Retz, M;Bokemeyer, C;Rödel, C;Hoffken, K
Bladder cancer The forgotten Tumor
Onkologe
2012
18
11
958-+

Retz, M;Bokemeyer, C
Second-line therapy of metastatic bladder cancer
Onkologe
2012
18
11
1018-1022

Niegisch, G;Retz, M;Hartmann, A;Thalgott, M;Gschwend, J;Vom Dorp, F;Stöckle, M;Ohlmann, C;Bogemann, M;Balabanov, S;Ohmann, C;Albers, P
Second-line treatment of advanced urothelial cancer - safety of combinatory treatment with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09)
Eur Urol Suppl
2012
11
1
E866-U824

Herkommer, K;Dinkel, A;Hahn, A;Marten-Mittag, B;Herschbach, P;Gschwend, J
Fear of progression among long-term prostate cancer survivors: Illness perceptions, patients presumed cause of prostate cancer and family history as potential predictors
Eur Urol Suppl
2012
11
1
E674-U440

Heidenreich, A;Albers, P;Bokemeyer, C;Goebell, P;Gschwend, J;Miller, K;Müller, S;Otremba, B;Reuter, C;Trojan, L;Volkmer, B;Wirth, M
Cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen: Interim analysis on treatment associated side effects resulting from a compassionate-use programme (CUP)
Eur Urol Suppl
2012
11
1
E128-U519

Heck, MM;Nawroth, R;Bandur, M;Souchay, M;Vitzthum, L;Weirich, G;Schuster, T;Thalgott, M;Gschwend, J;Retz, M
Topography of molecularbiological micrometastases in lymph nodes of prostate cancer patients treated with radical prostatectomy and extended lymphadenectomy
Eur Urol Suppl
2012
11
1
E1013-U121

Grunwald, V;Kube, U;Eichelberg, C;Zürn, C;Gschwend, J
GOLD study: An international Phase III study of TKI258/Dovitinib versus Sorafenib in patients with metastatic renal cell cancer (mRCC) as third line therapy
Onkologie
2012
35 6
202-203

Hatzichristodoulou, G;Kuebler, H;Schwaibold, H;Wagenpfeil, S;Eibauer, C;Hofer, C;Gschwend, J;Treiber, U
NUCLEAR MATRIX PROTEIN 22 (NMP22) AS URINE-BASED TUMOR MARKER FOR DETECTION OF PRIMARY AND RECURRENT BLADDER CANCER: COMPARISON OF THE POINT-OF-CARE VERSION (BLADDERCHEK (R)) AND THE ELISA
J Urol
2012
187 S
4
E512-E512